1421312-35-7

Basic information

• Product Name: methyl 1-chloro-4-hydroxy-7-phenoxyisoquinoline-3-carboxylate
• Synonyms: methyl 1-chloro-4-hydroxy-7-phenoxyisoquinoline-3-carboxylate;4-hydroxy-1-methyl-7-phenoxy-3-Isoquinolinecarboxylic acid
• CAS NO: 1421312-35-7
• Molecular Formula: C₁₇H₁₃NO₄
• Molecular Weight: 329.73448
• EINECS: -0
• Mol File: 1421312-35-7.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 552.7±50.0 °C(Predicted)
• Appearance: /
• Density: 1.376±0.06 g/cm3(Predicted)
• PKA: 0.10±0.30(Predicted)
• CAS DataBase Reference: methyl 1-chloro-4-hydroxy-7-phenoxyisoquinoline-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 1-chloro-4-hydroxy-7-phenoxyisoquinoline-3-carboxylate(1421312-35-7)
• EPA Substance Registry System: methyl 1-chloro-4-hydroxy-7-phenoxyisoquinoline-3-carboxylate(1421312-35-7)

Safety Data

• Hazardous Substances Data: 1421312-35-7(Hazardous Substances Data)

Usage

General Description

Methyl 1-chloro-4-hydroxy-7-phenoxyisoquinoline-3-carboxylate is a chemical compound that belongs to the class of organic compounds known as phenolic ethers. These are aromatic compounds containing an ether group substituted with a benzene ring. This particular compound has the molecular formula C19H14ClNO4. methyl 1-chloro-4-hydroxy-7-phenoxyisoquinoline-3-carboxylate hasn't been widely studied or utilized, hence its known applications and toxicological data are very limited. As with all chemicals, necessary precautions should be taken while handling and storing this compound. More unequivocal scientific investigations are needed to explore its potential uses and impact.

Upstream product

• 60-18-4 L-tyrosine 
• 1080-06-4 L-Tyr-OMe 
• 660844-52-0 2-amino-3-(4-phenoxyphenyl)propionic acid methyl ester 
• 1455091-10-7 4-hydroxy-7-phenoxyisoquinoline-3-carboxylic acid methyl ester 
• 1455091-21-0 1-bromo-4-hydroxy-7-phenoxyisoquinoline-3-carboxylic acid methyl ester 
• 57830-14-5 5-phenoxy-3H-isobenzofuran-1-one 
• 64169-34-2 5-bromophthalide 
• 1455091-04-9 2-(chloromethyl)-4-phenoxybenzoic acid methyl ester 

Downstream Products

• 1421312-36-8 [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)amino]acetic acid methyl ester 
• 808118-40-3 [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid 

Relevant articles and documents

IMPROVED PROCESS FOR THE PREPARATION OF ROXADUSTAT

A synthetic route for the preparation of Roxadustat, or a pharmaceutically acceptable salt thereof. Each route involves several novel intermediates and avoids the use of column chromatography.

Method for preparing isoquinolinone compound

The invention provides a method for preparing an isoquinolinone compound. Specifically, the invention provides a method for preparing a compound as shown in a formula 3, which is characterized by comprising the following steps: 1) reacting a compound as shown in a formula 1 with acyl chloride to obtain a compound as shown in a formula 2; and 2) reacting the compound of the formula 2 with an aminolysis reagent selected from glycine, glycine derivatives, or a combination thereof, and then carrying out a hydrolysis reaction to obtain a compound of a formula 3. The method disclosed by the invention has the excellent technical effects of reasonable route, convenience, feasibility, high preparation yield and purity, suitability for industrial production and the like.

Preparation method of drug for chronic anemia

The invention discloses a synthesis method for a drug Roxadustat for chronic anemia. The synthesis method comprises the following steps: hydrolyzing and acidifying a compound shown as a formula 6 under the action of alkali to obtain a key intermediate compound shown as a formula 7; carrying out condensation reaction on the compound shown as the formula 7 and carbonyl diimidazole under suitable conditions to obtain an intermediate compound shown as a formula 8, and separating or not separating the compound shown as the formula 8 from a system to directly take part in subsequent reaction; and finally, reacting the product with glycine to obtain a final product Roxadustat shown as a formula 9. The preparation method has the advantages that the route efficiency is improved, the process cost isreduced, side products are reduced and the purity of a final product is favorably improved (The formula is shown in the description), wherein R2 in the compound shown as the formula 6 represents alkyl, and includes but not limited to methyl, ethyl, isopropyl, tertiary butyl or benzyl.